Evidence map›Paper›PMID 29170289›Full record

ArticleBMJ open2017

Use of driving-impairing medicines by a Spanish population: a population-based registry study.

Eduardo Gutierrez-Abejón, Francisco Herrera-Gómez, Paloma Criado-Espegel, F Javier Alvarez

Abstract read
In one paragraph

Article in BMJ open, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Benzodiazepines in the oral fluid of Spanish drivers.Substance abuse treatment, prevention, and policy · 2020
    Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Eduardo Gutierrez-AbejónTechnical Direction of Pharmaceutical Assistance, Gerencia Regional de Salud de Castilla y Leon, Valladolid, Spain.
Francisco Herrera-GómezPharmacology, Faculty of Medicine, Universidad de Valladolid, Valladolid, Castilla y León, Spain.
Paloma Criado-EspegelTechnical Direction of Pharmaceutical Assistance, Gerencia Regional de Salud de Castilla y Leon, Valladolid, Spain.
F Javier AlvarezPharmacology, Faculty of Medicine, Universidad de Valladolid, Valladolid, Castilla y León, Spain.ORCID http://orcid.org/0000-0002-7566-5678

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo assess the use of driving-impairing medicines (DIM) in the general population with special reference to length of use and concomitant use.

designPopulation-based registry study.

settingThe year 2015 granted medicines consumption data recorded in the Castile and León (Spain) medicine dispensation registry was consulted.

participantsMedicines and DIM consumers from a Spanish population (Castile and León: 2.4 million inhabitants). EXPOSURE: Medicines and DIM consumption. Patterns of use by age and gender based on the length of use (acute: 1-7 days, subacute: 8-29 days and chronic use: ≥30 days) were of interest. Estimations regarding the distribution of licensed drivers by age and gender were employed to determine the patterns of use of DIM.

resultsDIM were consumed by 34.4% (95% CI 34.3% to 34.5%) of the general population in 2015, more commonly with regularity (chronic use: 22.5% vs acute use: 5.3%) and more frequently by the elderly. On average, 2.3 DIM per person were dispensed, particularly to chronic users (2.8 DIM per person). Age and gender distribution differences were observed between the Castile and León medicine dispensation registry data and the drivers' license census data. Of all DIM dispensed, 83.8% were in the Anatomical Therapeutic Chemical code group nervous system medicines (N), which were prescribed to 29.2% of the population.

conclusionsThe use of DIM was frequent in the general population. Chronic use was common, but acute and subacute use should also be considered. This finding highlights the need to make patients, health professionals, health providers, medicine regulatory agencies and policy-makers at large aware of the role DIM play in traffic safety.

Indexed as

Automobile DrivingAccidents, TrafficAdultAgedAged, 80 and overAge FactorsFemaleHumansMaleMiddle AgedPrescription DrugsRegistriesSex FactorsSpainYoung AdultPrescription Drugsaccident, trafficautomobile drivingdriving-impairing medicinesdrug prescriptiondrug utilizationrisk assessment

Identifiers

PMID29170289
PMCPMC5719315

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.